BCCA Protocol Summary for Palliative Therapy for Germ Cell Cancers Using PACLitaxel and Gemcitabine

Protocol Code

UGUTAXGEM

Tumour Group

Genitourinary

Contact Physician

Dr. Christian Kollmannsberger
Dr. Bernie Eigl

ELIGIBILITY:

- Relapsed germ cell cancers not amenable to cure with surgery or chemotherapy
- Cisplatin-refractory (failed during 1st-line EP/BEP or after 2nd-line VIP/VEIP)
- Patients relapsed after BMT are potentially eligible
- A BCCA “Individual Use of Benefit Drug List Medication for an Undesignated Indication” form with appropriate clinical information for each patient must be approved.

EXCLUSIONS:

- PS 3-4
- Motor neuropathy
- ANC less than 1.5, PLT less than 100, AST greater than 4xULN, Bili greater than 35, or Creat greater than 180

TESTS:

- Weekly CBC; monitor creat, LFTs, AFP, HCG, neuropathy each cycle
- Relevant imaging for response q8weeks (baseline and alternate cycles)

PREMEDICATIONS:

- PACLitaxel must not be started unless the following drugs have been given:
  - 45 minutes prior to PACLitaxel:
    - dexamethasone 20 mg IV in 50 mL NS over 15 minutes
  - 30 minutes prior to PACLitaxel:
    - diphenhydrAMINE 50 mg IV and Ranitidine 50 mg IV in 50 mL NS over 20 minutes (compatible up to 3 hours when mixed in bag)
- Additional antiemetics not usually required.

TREATMENT:

- Cycle length four weeks, repeat every 28 days x 2 - 6 cycles.
- Discontinue if no response after 2 cycles.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACLitaxel</td>
<td>110 mg/m² (d1, 8, 15)</td>
<td>IV in 500 mL* NS over 1 hour (use non-DEHP bag and non-DEHP tubing with 0.22 micron or smaller in-line filter)</td>
</tr>
<tr>
<td>gemcitabine</td>
<td>1,000 mg/m² (d1, 8, 15)</td>
<td>IV in 250 mL NS over 30 min</td>
</tr>
</tbody>
</table>

*use 250 mL for doses less than 150 mg

BC Cancer Agency Protocol Summary UGUTAXGEM
Activated: 1 Nov 2001    Revised: 1 May 2017
Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency’s terms of use available at www.bccancer.bc.ca/legal.htm
DOSE MODIFICATIONS:

1. Hematological

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets (x10^9/L)</th>
<th>Dose (both drugs)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.5 and greater than or equal to 75</td>
<td>100% of previous cycle</td>
<td></td>
</tr>
<tr>
<td>1.0-1.49 and/or 50-74</td>
<td>75% of previous cycle</td>
<td></td>
</tr>
<tr>
<td>0.5-0.99 and/or 25-49</td>
<td>50% of previous cycle</td>
<td></td>
</tr>
<tr>
<td>less than 1.0 and/or less than 25</td>
<td>Omit (d8) or delay (d1)**</td>
<td></td>
</tr>
</tbody>
</table>

*a dose reduction for granulocytic fever or thrombocytopenia within a cycle results in a reduction of 25% in the start dose of the next cycle

**if day 15, omit and start next cycle on day 22 instead of day 29

2. Gastrointestinal Toxicities

<table>
<thead>
<tr>
<th>Grade</th>
<th>Stomatitis</th>
<th>Diarrhea</th>
<th>Dose Gemcitabine</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Painless ulcers, erythema or mild soreness</td>
<td>Increase of 2-3 stools/day or mild increase in loose watery colostomy output</td>
<td>100%</td>
</tr>
<tr>
<td>2</td>
<td>Painful erythema, edema, or ulcers but can eat</td>
<td>Increase of 4-6 stools, or nocturnal stools or mild increase in loose watery colostomy output</td>
<td>Omit until toxicity resolved then resume at 100%</td>
</tr>
<tr>
<td>3</td>
<td>Painful erythema, edema, or ulcers and cannot eat</td>
<td>Increase of 7-9 stools/day or incontinence, malabsorption; or severe increase in loose watery colostomy output</td>
<td>Omit until toxicity resolved then resume at 75%</td>
</tr>
<tr>
<td>4</td>
<td>Mucosal necrosis, requires parenteral support</td>
<td>Increase of 10 or more stools/day or grossly bloody diarrhea, or grossly bloody colostomy output or loose watery colostomy output requiring parenteral I support; dehydration</td>
<td>Omit until toxicity resolved then resume at 50%</td>
</tr>
</tbody>
</table>

3. Other Non-Hematological Toxicities: dose modifications recommended for

- LFTs greater than or equal to 2 x ULN
- nausea Grade 4
- myalgia/rash Grade 3
- other toxicities of Grade 2-4 severity (excluding alopecia)

For more details, consult Table 2 of the referenced article.

PRECAUTIONS:

1. Hypersensitivity: Reactions are common with PACLitaxel. See BCCA Hypersensitivity Guidelines.
2. Extravasation: PACLitaxel causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines.
3. Neutropenia: Fever or other evidence of infection must be assessed promptly and treated aggressively.
4. Thrombocytopenia: platelet support may be required as per local guidelines.
5. Renal Dysfunction: Irreversible renal failure associated with hemolytic uremic syndrome may occur with gemcitabine (rare). Use caution with pre-existing renal dysfunction.
6. Pulmonary Toxicity: Acute shortness of breath may occur. Discontinue treatment if gemcitabine-induced pneumonitis is suspected.
7. **Arthralgia and/or Myalgia**: if unrelieved by acetaminophen ± codeine, try
   - Prednisone 10 mg po bid x 5 days starting 24 hours post-PACLitaxel
   - Gabapentin 300 mg po on day before chemotherapy, 300 mg bid on treatment day, then 300 mg tid x 7-10 days

8. **Neuropathy**: Dose modification or discontinuation may be required (see BCCA Cancer Drug Manual).

   **Contact Dr. Christian Kollmannsberger, Dr. Bernie Eigl** or tumour group delegate at (604) 877-2730 or 1-800-663-3333 with any problems or questions regarding this treatment program.

---

**Date activated:** 01 Nov 2002

**Date revised:** 1 May 2017 (Contact physician updated)

**Reference:**